Westwood Holdings Group Inc. Decreases Position in Avanos Medical, Inc. (NYSE:AVNS)

Westwood Holdings Group Inc. lessened its holdings in Avanos Medical, Inc. (NYSE:AVNS - Free Report) by 36.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,260,569 shares of the company's stock after selling 730,486 shares during the quarter. Westwood Holdings Group Inc. owned 2.74% of Avanos Medical worth $20,068,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently modified their holdings of the company. Barclays PLC increased its stake in Avanos Medical by 446.2% in the 3rd quarter. Barclays PLC now owns 96,194 shares of the company's stock worth $2,311,000 after purchasing an additional 78,583 shares during the period. JPMorgan Chase & Co. increased its stake in Avanos Medical by 6.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 69,571 shares of the company's stock worth $1,672,000 after purchasing an additional 4,472 shares during the period. Tributary Capital Management LLC increased its stake in shares of Avanos Medical by 38.1% in the fourth quarter. Tributary Capital Management LLC now owns 893,008 shares of the company's stock worth $14,217,000 after buying an additional 246,379 shares during the period. Empowered Funds LLC increased its stake in shares of Avanos Medical by 141.3% in the fourth quarter. Empowered Funds LLC now owns 153,834 shares of the company's stock worth $2,449,000 after buying an additional 90,091 shares during the period. Finally, New York State Teachers Retirement System increased its stake in shares of Avanos Medical by 4.0% in the fourth quarter. New York State Teachers Retirement System now owns 75,215 shares of the company's stock worth $1,197,000 after buying an additional 2,921 shares during the period. Hedge funds and other institutional investors own 95.17% of the company's stock.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded shares of Avanos Medical from a "hold" rating to a "buy" rating in a research report on Wednesday, March 19th.

Avanos Medical Price Performance

AVNS opened at $13.00 on Tuesday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.46 and a current ratio of 2.22. The stock's 50 day moving average price is $13.16 and its 200-day moving average price is $15.66. The stock has a market capitalization of $601.17 million, a PE ratio of 38.24 and a beta of 1.13. Avanos Medical, Inc. has a 52-week low of $11.84 and a 52-week high of $25.36.

Avanos Medical (NYSE:AVNS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.19 by $0.07. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%. The business had revenue of $167.50 million for the quarter, compared to the consensus estimate of $161.75 million. During the same period in the previous year, the firm earned $0.22 EPS. The company's quarterly revenue was up .8% compared to the same quarter last year. On average, equities research analysts predict that Avanos Medical, Inc. will post 1.32 EPS for the current year.

Insider Buying and Selling

In other news, SVP Kerr Holbrook sold 7,000 shares of the company's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $15.25, for a total value of $106,750.00. Following the sale, the senior vice president now directly owns 82,047 shares of the company's stock, valued at $1,251,216.75. This represents a 7.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 2.64% of the stock is owned by insiders.

About Avanos Medical

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.